What is CAR-T cell therapy and who is eligible

May 19, 2026Navis AI

Ask Navis about your situation

This answer is general. Get one about your specific case — no signup, answered right here.

For informational purposes only

This answer was generated by AI grounded in NCCN guidelines and published medical literature. It is not medical advice. Always consult your oncologist or care team before making treatment decisions.

CAR-T Cell Therapy: What It Is and Who Can Receive It

How CAR-T Therapy Works

CAR-T cell therapy is a type of immunotherapy that uses your own immune cells to fight cancer. Here's the basic process:

  1. Extraction: Doctors collect T cells (a type of white blood cell) from your blood
  2. Engineering: These cells are sent to a lab where scientists add a special receptor called a CAR (Chimeric Antigen Receptor) to their surface—think of it like adding a "targeting system" to help them recognize cancer cells
  3. Expansion: The modified cells are grown in large numbers in the lab
  4. Reinfusion: The CAR-T cells are returned to your body where they circulate and attack cancer cells that match their target

The key advantage is that these cells can recognize specific markers on cancer cells and keep multiplying to fight the disease.

Current FDA-Approved CAR-T Therapies

According to the National Cancer Institute (NCI), CAR-T therapies are currently approved for:

  • Blood cancers (leukemias and lymphomas):

    • Certain types of acute lymphoblastic leukemia (ALL)
    • Certain types of non-Hodgkin lymphoma
    • Multiple myeloma
    • Chronic lymphocytic leukemia (CLL)
  • Solid tumors: Research is ongoing, but currently limited FDA approvals exist for solid tumors

Who Is Eligible?

General eligibility criteria typically include:

  • Diagnosis: You must have one of the approved cancer types
  • Disease status: Usually patients with relapsed or refractory disease (cancer that came back or didn't respond to standard treatments)
  • Overall health: You need adequate organ function (heart, liver, kidney) to tolerate the therapy
  • Performance status: You must be well enough to undergo the treatment process
  • No active infections: Active infections can complicate treatment
  • CNS involvement: Depending on the type, active brain/spinal cord involvement may exclude you

Important note: Each CAR-T product has specific eligibility requirements. For example, some are approved only for patients who have failed prior therapies, while others may be considered earlier in treatment.

Key Questions to Ask Your Oncology Team

If you're considering CAR-T therapy:

  1. Am I eligible for CAR-T therapy based on my specific cancer type and disease status?
  2. Which CAR-T product would be most appropriate for my situation?
  3. What are the potential side effects, and how are they managed? (CAR-T can cause serious side effects like cytokine release syndrome)
  4. How long does the entire process take from cell collection to reinfusion?
  5. What is the expected response rate and durability for patients like me?
  6. Are there clinical trials available that might be an option?

Where to Learn More

The NCCN (National Comprehensive Cancer Network) Guidelines provide detailed recommendations for CAR-T eligibility based on specific cancer types. The American Cancer Society also offers patient-friendly information about immunotherapy options.


This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.

Ask Navis about your case

That answer is general. Ask about your specific situation — no signup, answered right here.

Facing this with someone you love?

Keep the whole picture in one private place: records, a plain-language summary of where things stand, questions, and the people helping. Navis keeps it up to date so no one has to re-explain the story. Free, and only the people you invite can ever see it.

Start a care circle →

Related Questions

Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...

```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv

Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...

```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv

Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...

```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv

Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...

```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv

Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...

```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv

We are in the UK royal marsden. It is kind of hopeless or how to say? Is there any immunetherapy worth to pursue or...

TL;DR: Diffuse midline gliomas DMGs with H3K27M are very challenging, but immunotherapy and targeted approaches are actively being researched—the Roya

It is my daughter she completed 6 weeks of radio and tmz now she is on 3rd cycle of tmz 200mg. We are doing low meth...

TL;DR: Your daughter's treatment plan radiation + TMZ chemotherapy is standard for diffuse midline glioma, and her biomarkers MGMT methylated, EGFR A2

It is h3k27 altered dmg h3k27m negative, egfr a289v myc tp53 mgmt methylated

Your tumor has specific genetic changes H3K27, EGFR, MYC, TP53, MGMT that your doctors will use to guide treatment decisions—these findings help deter